Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 6/2016

29.11.2016 | T-CELL AND OTHER LYMPHOPROLIFERATIVE MALIGNANCIES (P PORCU, SECTION EDITOR)

Enteropathy-Associated T-Cell Lymphoma

verfasst von: Sarah Ondrejka, Deepa Jagadeesh

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Enteropathy-associated T-cell lymphoma is a rare neoplasm with uniformly aggressive features that arises from intestinal T-cells. There is strong evidence supporting its association as a dire complication of celiac disease. The clinical presentation can vary from malabsorption and abdominal pain to an acute abdominal emergency. Originally, it was divided into types I and II in World Health Organization (WHO) classification schemes, reflective of epidemiology and differences in clinicopathologic features. The debate over the degree of separation of the two types is ongoing as new data emerges regarding the pathogenetics. The low incidence and variable patient factors are major barriers in conducting clinical trials and establishing standard treatment regimens. Yet, the collective experience demonstrates favorable outcomes with combination chemotherapy followed by an autologous hematopoietic stem cell transplant in patients who can tolerate such treatment. The prognosis remains dismal; thus, future research studies are warranted to identify effective novel therapies that can improve outcomes in this rare disease entity.
Literatur
1.
Delabie J et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148–55.CrossRefPubMed
2.
Lee M-Y, Tsou M-H, Tan T-D, Lu M-C. Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma. Eur J Haematol. 2005;75:221–6.CrossRefPubMed
3.
Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803.PubMed
4.
Tse E et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87:663–8.CrossRefPubMed
5.
Isaacson PG, Chott A, Ott G, Stein H. In World Health Organization classification of tumours of the haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J, editors. IARC; 2008. p. 289–91.
6.
Sharaiha RZ et al. Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. Cancer. 2012;118:3786–92.CrossRefPubMed
7.
Silano M, Volta U, DeVincenzi A, Dessi M. D. M. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53:972–6.CrossRefPubMed
8.
Lebwohl B, Granath F, Ekbom A, Smedby KE, Murray JA, Neugut AI, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease. Ann Intern Med. 2013;159:169–75.CrossRefPubMedPubMedCentral
9.
Chan JKC et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35:1557–69.CrossRefPubMed
10.
Sun J, Lu Z, Yang D, Chen J. Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol. 2011;24:983–92.CrossRefPubMed
11.
Tan S-Y et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27:1688–96.CrossRefPubMed
12.
Deleeuw RJ et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132:1902–11.CrossRefPubMed
13.
Swerdlow SH et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014;38:e60–71.CrossRefPubMed
14.
Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMed
15.
Biagi F, Lorenzini P. C. G. Literature review on the clinical relationship between ulcerative jejunitis, coeliac disease and enteropathy associated T cell lymphoma. Scand J Gastroenterol. 2000;35:785–90.CrossRefPubMed
16.
Sabatino AD, Biagi F, Gobbi PG, C. G. How I treat enteropathy-associated T-cell lymphoma. Blood2. 2012;119:2458–68.CrossRef
17.
Malamut G, Meresse B, Cellier C, Cerf-Bensussan N. Refractory celiac disease: from bench to bedside. Semin Immunopathol. 2012;34:601–13.CrossRefPubMed
18.
Roshan B et al. The incidence and clinical spectrum of refractory celiac disease in a North American referral center. Am J Gastroenterol. 2011;106:923–8.CrossRefPubMed
19.
Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136:81–90.CrossRefPubMed
20.
Green PH et al. Risk of malignancy in patients with celiac disease. Am J Med. 2003;115:191–5.CrossRefPubMed
21.
Olen O et al. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis. 2011;43:862–8.CrossRefPubMed
22.
Sieniawski M et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664–70.CrossRefPubMed
23.
Wierdsma NJ et al. Refractory celiac disease and EATL patients show severe malnutrition and malabsorption at diagnosis. Clin Nutr. 2016;35:685–91.CrossRefPubMed
24.
Muller-Hermelink H, Delabie J, Ko Y, et al. WHO classification of tumours of the digestive system 112–4 (IARC, 2010).
25.
Ondrejka SL, Moffitt AB, Tse E, Hsi ED, Goodlad JR, au-Yeung R, Kwong Y-L, Srivastava G. Gascoyne R, Rajagopalan D, Love C, Dave S. Whole exome sequencing of type I and type II enteropathy-associated T-cell lymphoma reveals genetic basis of oncogenesis 622 (American Society of Hematology, ASH oral presentation 2015).
26.
Howat AJ, McPhie JL, Smith DA, et al. Cavitation of mesenteric lymph nodes: a rare complication of coeliac disease, associated with a poor outcome. Histopathology1 146, 509–519 (995).
27.
Zettl A, Ott G, Makulik A, Katzenberger T, Starostik P, Eichler T, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161:1635–45.CrossRefPubMedPubMedCentral
28.
29.
Zettl A, de Leeuw R, Haralambieva EM-HH. Enteropathy-type T-cell lymphoma. Am J Clin Pathol. 2007;127:701–6.CrossRefPubMed
30.
Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology. 2015;66:112–36.CrossRefPubMed
31.
Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137:1227–31.CrossRefPubMed
32.
Malamut G et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377–84.CrossRefPubMed
33.
Tomita S et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28:1286–96.CrossRefPubMed
34.
Tan SY, Ooi AS, Ang MK, et al. Nuclear expression of MATK is a novel marker of type II enteropathy associated T-cell lymphoma. Leukemia. 2011;25:555–7.CrossRefPubMed
35.
Kikuma K, Yamada K, Nakamura S, Ogami A, et al. Detailed clinicopathologic characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2013;45:1274–84.
36.
Küçük C et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun. 2015;6:6025.CrossRefPubMed
37.
Nairismägi M-L et al. JAK-STAT and G protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 2016;30:1311–9.CrossRefPubMedPubMedCentral
38.
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126:17–25.CrossRefPubMed
39.
40.
Mansoor A et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447–52.CrossRefPubMedPubMedCentral
41.
Leventaki V et al. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol. 2014;45(2):421–6.CrossRefPubMed
42.
Takeuchi K et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631–7.CrossRefPubMed
43.
44.
Hadithi M et al. The value of double-balloon enteroscopy in patients with refractory celiac disease. Am J Gastroenterol. 2007;102:987–96.CrossRefPubMed
45.
Hadithi M et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47:1622–7.PubMed
46.
Hoffmann M et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52:347–51.CrossRefPubMedPubMedCentral
47.
Van Weyenberg SJB et al. MR enteroclysis in refractory celiac disease: proposal and validation of a severity scoring system. Radiology. 2011;259:151–61.CrossRefPubMed
48.
Jantunen E et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32.CrossRefPubMed
49.
d’Amore F et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.CrossRefPubMed
50.
Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.CrossRefPubMed
51.
Karanam PK, Al-Hamadani M, Go RS. Enteropathy-associated T-cell lymphoma in the US: higher incidence and poorer survival among Asians. Br J Haematol. 2016;172:990–2.CrossRefPubMed
52.
Verbeek WHM et al. Aberrant T-lymphocytes in refractory coeliac disease are not strictly confined to a small intestinal intraepithelial localization. Cytometry B Clin Cytom. 2009;76:367–74.CrossRefPubMed
53.
Verbeek WHM et al. The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease. Am J Gastroenterol. 2008;103:3152–8.CrossRefPubMed
54.
Pongpruttipan T et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36:481–99.CrossRefPubMed
Metadaten
Titel
Enteropathy-Associated T-Cell Lymphoma
verfasst von
Sarah Ondrejka
Deepa Jagadeesh
Publikationsdatum
29.11.2016
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2016
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-016-0357-7

Weitere Artikel der Ausgabe 6/2016

Current Hematologic Malignancy Reports 6/2016 Zur Ausgabe

Myelodysplastic Syndromes (D Steensma, Section Editor)

Assessing Quality of Care for the Myelodysplastic Syndromes

Acute Myeloid Leukemias (H Erba, Section Editor)

Definition of Unfit for Standard Acute Myeloid Leukemia Therapy

Acute Myeloid Leukemias (H Erba, Section Editor)

Antibody-Based Treatment of Acute Myeloid Leukemia

Myelodysplastic Syndromes (D Steensma, Section Editor)

Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms

Myelodysplastic Syndromes (D Steensma, Section Editor)

Molecular Testing in Patients with Suspected Myelodysplastic Syndromes

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Sézary Syndrome: Clinical and Biological Aspects

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise